Journal
FRONTIERS IN BIOSCIENCE-LANDMARK
Volume 19, Issue -, Pages 687-706Publisher
FRONTIERS IN BIOSCIENCE INC
DOI: 10.2741/4236
Keywords
Focal Adhesion Kinase; Cancer; Metastasis; Small molecule inhibitors; Angiogenesis; Survival; Review
Categories
Funding
- NCI RO-1 grants [CA65910]
- NCI Cancer Center Support grant [CA 16056]
- NATIONAL CANCER INSTITUTE [P30CA016056, R01CA065910] Funding Source: NIH RePORTER
Ask authors/readers for more resources
It is twenty years since Focal Adhesion Kinase (FAK) was found to be overexpressed in many types of human cancer. FAK plays an important role in adhesion, spreading, motility, invasion, metastasis, survival, angiogenesis, and recently has been found to play an important role as well in epithelial to mesenchymal transition (EMT), cancer stem cells and tumor microenvironment. FAK has kinase-dependent and kinase independent scaffolding, cytoplasmic and nuclear functions. Several years ago FAK was proposed as a potential therapeutic target; the first clinical trials were just reported, and they supported further studies of FAK as a promising therapeutic target. This review discusses the main functions of FAK in cancer, and specifically focuses on recent novel findings on the role of FAK in cancer stem cells, microenvironment, epithelial-to-mesenchymal transition, invasion, metastasis, and also highlight new approaches of targeting FAK and critically discuss challenges that lie ahead for its targeted therapeutics. The review provides a summary of translational approaches of FAK-targeted and combination therapies and outline perspectives and future directions of FAK research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available